Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus

被引:59
作者
Guo, Hongbo
Zhu, Hui
Xi, Yan
Zhang, Baijiang
Li, Ling
Huang, Yong
Zhang, Jiandong
Fu, Zheng
Yang, Guoren
Yuan, Shuanghu
Yu, Jinming
机构
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Shandong 250117, Peoples R China
[2] Shandong Canc Hosp & Inst, Dept Thorac Surg, Jinan, Peoples R China
[3] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[4] Shandong Canc Hosp & Inst, Dept Nucl Med, Jinan, Peoples R China
关键词
gastroenterology; PET/CT; esophageal squamous cell carcinoma; relapse; prognosis;
D O I
10.2967/jnumed.106.036509
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Patients with esophageal squamous cell carcinoma (ESCC) are commonly at high risk of recurrence within 2 y after initial treatment. The aim of this study was to evaluate the role of F-18-FDG PET/CT in patients with possibly recurrent ESCC who underwent definitive treatment. Methods: Fifty-six patients with previously treated ESCC underwent PET/CT scans. The PET/CT findings were validated by histopathology or clinical follow-up of at least 6 mo. The sensitivity, specificity, and accuracy of PET/CT for detecting recurrence were calculated. Comparison of the standardized uptake value (SUV) was performed between patients grouped according to their status at the last follow-up (relapsed or relapse-free, alive or dead). The overall survival rates were estimated by the Kaplan-Meier method. The Cox proportional hazards model was used to evaluate independent prognostic variables for both univariate and multivariate survival analysis. Results: Forty-five (80.4%) patients had recurrence in 72 (66.1 %) malignant sites. On PET/CT, there were 9 false-positive and 5 false-negative results. The overall sensitivity, specificity, and accuracy of PET/CT for detecting recurrence at all sites were 93.1% (67/72), 75.7% (28/37), and 87.2% (95/109), respectively. PET/CT was highly sensitive, specific, and accurate at regional and distant sites. At local sites, sensitivity was high, but specificity was lower (50%) because of a high incidence of false-positive findings. Patients who were confirmed with recurrence or who had died at the last follow-up had higher SUVs (P = 0.027 and <0.001, respectively). In multivariate survival analysis, therapeutic modality (hazard ratio = 0.437; P = 0.044), SUV (hazard ratio = 1.071; P = 0.029), and disease status on PET/ CT (hazard ratio = 2.430; P = 0.045) were independent significant prognostic predictors for overall survival. The Kaplan-Meier survival curves indicated poor prognostic outcome in subgroup patients with higher SUVs or systemic disease on PET/CT. Conclusion: F-18-FDG PET/CT is highly effective for detecting recurrent ESCC. The relatively low specificity at local sites is associated primarily with a high rate of false-positive interpretations at anastomoses. PET/CT can also provide noninvasive and independent prognostic information using SUV and recurrent disease pattern on PET/CT images for previously treated ESCC.
引用
收藏
页码:1251 / 1258
页数:8
相关论文
共 25 条
[1]   En bloc esophagectomy improves survival for stage III esophageal cancer [J].
Altorki, NK ;
Girardi, L ;
Skinner, DB .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (06) :948-955
[2]  
Beyer T, 2000, J NUCL MED, V41, P1369
[3]   A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer [J].
Blackstock, AW ;
Farmer, MR ;
Lovato, J ;
Mishra, G ;
Melin, SA ;
Oaks, T ;
Aklilu, M ;
Clark, PB ;
Levine, EA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (02) :455-460
[4]  
Buenaventura P, 2000, Chest Surg Clin N Am, V10, P487
[5]   RECURRENT ESOPHAGEAL-CARCINOMA - CT EVALUATION AFTER ESOPHAGECTOMY [J].
CARLISLE, JG ;
QUINT, LE ;
FRANCIS, IR ;
ORRINGER, MB ;
SMICK, JF ;
GROSS, BH .
RADIOLOGY, 1993, 189 (01) :271-275
[6]   Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma [J].
Cremerius, U ;
Fabry, U ;
Neuerburg, J ;
Zimny, M ;
Osieka, R ;
Buell, U .
NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (11) :1055-1063
[7]   Gastrointestinal tract malignancies and positron emission tomography: An overview [J].
Esteves, FP ;
Schuster, DM ;
Halkar, RK .
SEMINARS IN NUCLEAR MEDICINE, 2006, 36 (02) :169-181
[8]   The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer [J].
Flamen, P ;
Lerut, A ;
van Custem, E ;
Cambier, JP ;
Maes, A ;
De Wever, W ;
Peeters, M ;
De Leyn, P ;
Van Raemdonck, D ;
Mortelmans, L .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2000, 120 (06) :1085-1092
[9]   Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions - A meta-analysis [J].
Gould, MK ;
Maclean, CC ;
Kuschner, WG ;
Rydzak, CE ;
Owens, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (07) :914-924
[10]  
Heeren PAM, 2004, J NUCL MED, V45, P980